---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-010868"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T12:22:20.400189+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Telomir-1 reduces tumor size ~50% in prostate cancer model; protects against chemo toxicity

## Summary
- Telomir-1 alone (low and high doses) reduced tumor growth ~50% in aggressive human prostate cancer animal model.
- Contrary to concerns, Telomir-1 suppressed tumor development and selectively benefited healthy cells.
- Paclitaxel alone caused severe toxicity with one-third mortality; adding low-dose Telomir-1 eliminated mortality.
- Telomir-1 combined with Paclitaxel neutralized chemotherapy-induced toxicity and weight loss.
- Results position Telomir-1 as a potential adjunct to standard chemotherapy for prostate cancer.

## SEC filing metadata
- accession: 0001493152-25-010868
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225010868/0001493152-25-010868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225010868/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-010868
- JSON: https://secwatch.observer/filing/0001493152-25-010868.json
- Plain text: https://secwatch.observer/filing/0001493152-25-010868.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.